Tapahtumakalenteri

Paul Workman is Harrap Professor of Pharmacology and Therapeutics and Group Leader of the Signal Transduction and Molecular Pharmacology Team at The Institute of Cancer Research (ICR), London. Until August 2021, he served for seven years as Chief Executive and President of ICR, and for almost twenty years he was Director of ICR’s CRUK Cancer Therapeutics Unit, the world’s largest academic cancer drug discovery centre. Paul was also Founding Director of the CRUK Convergence Science Centre at ICR/Imperial College and is currently Co-Director of the CRUK Children’s Brain Tumour Centre of Excellence at ICR and Cambridge University.  Paul is an internationally recognised leader in the multidisciplinary discovery, molecular pharmacology and chemical biology of cancer drugs and has been instrumental in the discovery of multiple clinical drug candidate acting on protein kinases, PI3 kinases, the molecular chaperone HSP90, and the Integrated Stress Response/Heat Shock Factor 1 pathway. He has published >500 research articles garnering >55K citations and his h-index is 119. Paul has received multiple honours and awards – he is an elected Fellow of the Royal Society (the UK’s national science academy), Fellow of the Academy of Medical Sciences and Fellow of the American Association for the Advancement of Science, and is a CRUK Life Fellow.

Paul obtained his BSc in Biological Sciences at the University of Leicester UK and his PhD in Cancer Pharmacology at the University of Leeds UK. He has previously worked at the MRC Clinical Oncology Unit, Cambridge University; CRUK Beatson Laboratories, Glasgow University; Stanford University and SRI International (UICC ICRETT Fellow); and Zeneca Pharmaceuticals. He is a scientific founder of Chroma Therapeutics and Piramed Pharma (acquired by Roche). Paul has developed public resources for translational research and drug discovery – he is Director of the nonprofit Chemical Probes Portal (www.chemicalprobes.org) and co-developer of canSAR (www.cansar.ai) and Probe Miner (https://probeminer.icr.ac.uk).

Welcome to this exciting seminar! 

Juha Saarikangas

Selected Recent Publications

1. Workman P*. The NCI-60 Human Tumor Cell Line Screen: A Catalyst for Progressive Evolution of Models for Discovery and Development of Cancer Drugs. Cancer Res. 2023 Oct 2;83(19):3170-3173. doi: 10.1158/0008-5472.CAN-23-2612. PMID: 37779429 (*Senior author).
2. Mader MM, Rudolph J, Hartung IV, Uehling D, Workman P, Zuercher W. Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation. Cancer Discov. 2023 Oct 5;13(10):2150-2165. doi: 10.1158/2159-8290.CD-23-0536. PMID: 37712569. 
3. Hartung IV, Rudolph J, Mader MM, Mulder MPC, Workman P. Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes. J Med Chem. 2023 Jul 27;66(14):9297-9312. doi: 10.1021/acs.jmedchem.3c00550. Epub 2023 Jul 5. PMID: 37403870. 
4. Pasqua AE, Sharp SY, Chessum NEA, Hayes A, Pellegrino L, Tucker MJ, Miah A, Wilding B, Evans LE, Rye CS, Mok NY, Liu M, Henley AT, Gowan S, De Billy E, Te Poele R, Powers M, Eccles SA, Clarke PA, Raynaud FI, Workman P*, Jones K, Cheeseman MD. HSF1 pathway inhibitor clinical candidate (CCT361814/NXP800) developed from a phenotypic screen as a potential treatment for refractory ovarian cancer and Other Malignancies. J Med Chem. 2023 Apr 27;66(8):5907-5936. doi: 10.1021/acs.jmedchem.3c00156. Epub 2023 Apr 5. PMID: 37017629 (*Joint senior author). 
5. di Micco P, Antolin AA, Mitsopoulos C, Villasclaras-Fernandez E, Sanfelice D, Dolciami D, Ramagiri P, Mica IL, Tym JE, Gingrich PW, Hu H, Workman P*, Al-Lazikani B. canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Res. 2023 Jan 6;51(D1):D1212-D1219. doi: 10.1093/nar/gkac1004. PMID: 36624665 (*Joint senior author).
   
   
   ************************************
   
   University of Helsinki students please note: If you wish to obtain credits (DPBM, ILS) from this webinar series, please rename yourself in Zoom with first name + last name (do not use nickname/user ID/student number/just first name).